All In Biotech

Drug Trial Radar · NCT07344051

A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of QLS12010 Capsules in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Apr 5, 2026

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial was designed to evaluate the efficacy and safety of QLS12010 Capsules in adults with moderate-to-severe atopic dermatitis.

Conditions

  • Moderate-to-severe Atopic Dermatitis

Interventions

  • QLS12010Drug

    QLS12010 oral capsule

  • PlaceboDrug

    Matching placebo oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 16.Time frame: At Week 16.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.